The agreement provides for a close working relationship between Genzyme and Arecor in developing stable, high strength formulations of labile biomolecules.
Both the parties said that the agreement is the result of a two year working relationship where Arecor has demonstrated its technologies offer an improvement over conventional approaches in protein formulation.
Robert Mattaliano, group vice president of therapeutic protein R&D at Genzyme, said: “The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles. Genzyme is pleased to establish this strategic partnership in support of our goal to provide stable and convenient dosage forms to patients and their caregivers.”
Tom Saylor, CEO of Arecor, said: “Formulation of the next generation of biologics represents unique challenges to developers. Arecor has developed a strong partnership with Genzyme and is privileged to work closely with one of the world leaders in biotechnology to help enable new protein-based therapeutics.”